com have "2015 Market Report on Global Clopidogrel Bisulfate
Industry" added to its research database.
Plavix, whose chemical name is clopidogrel bisulfate
, is the biggest seller for Bristol-Myers and second-biggest for Paris-based Sanofi, behind the Lovenox clot treatment.
Among other revisions, under the terms of the modified agreement, Apotex's license to manufacture and sell its FDA approved clopidogrel bisulfate
product in the United States would be effective on June 1, 2011, rather than September 17, 2011, as disclosed in the press release issued by the companies on March 21, 2006.
This new study will provide clinicians with additional information regarding the interaction potential between dexlansoprazole, lansoprazole, esomeprazole, and omeprazole with clopidogrel bisulfate
is a prescription antiplatelet medicine taken once a day that helps keep platelets in the blood from sticking together and forming clots.
9 /PRNewswire/ -- Prism Pharmaceuticals announced today that the results of the first-in-man study of PM103, a novel intravenous formulation of clopidogrel bisulfate
(the active ingredient in PLAVIX(R)), has been accepted for poster presentation at the 58th Scientific Session of the American College of Cardiology (ACC) on March 29-31, 2009.
, levothyroxine sodium, Montelukast sodium
Generic clopidogrel bisulfate
in the distribution channels is substantially depleted as reflected in the second quarter results.
patent 4,847,265 covering clopidogrel bisulfate
, the active ingredient in Plavix(R), maintaining the main patent protection for this product in the United States until November 2011.
Jain's poster focused on an intravenous formulation of clopidogrel bisulfate
, developed by Acusphere using its proprietary technology.
PLAVIX(R) net sales in the first quarter of 2007 have increased by 129% compared to $343 million in the fourth quarter of 2006 as generic clopidogrel bisulfate
inventory in the distribution channels is depleted.
The lawsuit relates to the validity of a patent for clopidogrel bisulfate
(the '265 patent) sold in the United States as PLAVIX(R).